RT Journal Article
SR Electronic
T1 Beyond Deaths per Capita: Comparative CoViD-19 Mortality Indicators
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20085506
DO 10.1101/2020.04.29.20085506
A1 Heuveline, Patrick
A1 Tzen, Michael
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.04.29.20085506.abstract
AB The number of CoViD-19 deaths more reliably tracks the progression of the disease across populations than the number of confirmed cases, but substantial age and sex differences in CoViD-19 mortality imply that the number of deaths should be adjusted for the age-and-sex composition of the population as well as its total size. Following well-established practices in demography, this article discusses several measures based on the cumulative number of CoViD-19 deaths and illustrate them with data from 362 national and subnational populations. The first measure is an unstandardized occurrence/exposure rate comparable to the Crude Death Rate. To date, we measured the highest value in New York, exceeding at its peak the state’s most recent annual Crude Death Rate. The second measure is an indirectly standardized rate which we show to perform quite like a directly standardized rate but without requiring a breakdown of CoViD-19 deaths by age and sex. Either way, standardization substantially modifies comparisons across populations: New Jersey has the highest unstandardized rate to date, but four states in Mexico and one in Brazil have higher standardized rates. Finally, extant life tables allow to estimate reductions in 2020 life expectancies, which are projected to exceed two years for New York, New Jersey and Peru, and possibly three years in Ecuador. To put these in perspective, with a 1.1-year projected reduction, the US life expectancy at birth should have in 2020 its largest annual decline since World War II and reach its lowest level since 2006.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm